TearLab Corporation (TEAR) Issues Quarterly Earnings Results

TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) announced its quarterly earnings results on Monday. The medical research company reported ($0.67) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.06, Bloomberg Earnings reports.

Shares of TearLab Corporation (NASDAQ TEAR) traded up $0.11 during midday trading on Tuesday, reaching $0.84. 190,901 shares of the company traded hands, compared to its average volume of 245,077. The company has a debt-to-equity ratio of -2.03, a quick ratio of 2.14 and a current ratio of 2.60. TearLab Corporation has a fifty-two week low of $0.59 and a fifty-two week high of $7.50.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research lowered shares of TearLab Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of TearLab Corporation in a research note on Tuesday, August 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $4.90.

COPYRIGHT VIOLATION NOTICE: “TearLab Corporation (TEAR) Issues Quarterly Earnings Results” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://transcriptdaily.com/2017/11/14/tearlab-corporation-tear-issues-quarterly-earnings-results.html.

About TearLab Corporation

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Earnings History for TearLab Corporation (NASDAQ:TEAR)

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply